Live Analyst Rating Changes 36214 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Arthur He CFA
HC

Arthur He CFA

H.C. Wainwright
Wall Street Analyst
★★☆☆☆
#2667
on 13Foresight · ranked by our own returns
38%
Success Rate
-5.0%
Average Return
12 of 32 calls profitable · +22.6% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 38% of Arthur He CFA's ratings turned a profit when each position was held for 1 year — averaging -5.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

48 Buy 4 Hold 0 Sell
Arthur's Stock Coverage 13 ratings · 2026-10-01
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
PRME
Prime Medicine, Inc.
 Oct 01, 2026 BUY Strong Buy
+211.2% avg upside
18 analysts
$8.00
161.40% Upside
 · ·
JBIO
Jade Biosciences
 Oct 01, 2026 BUY Strong Buy
+319.1% avg upside
16 analysts
$55.00
301.85% Upside
 · ·
NKTR
Nektar Therapeutics
 Oct 01, 2026 BUY Strong Buy
+34.0% avg upside
26 analysts
$185.00
276.68% Upside
 · ·
TSE:MSCL
Satellos Bioscience
 Sep 25, 2026 BUY Strong Buy
+155.0% avg upside
8 analysts
$25.55
112.63% Upside
 +0.0% ·
SLDB
Solid Biosciences
 Sep 14, 2026 BUY Strong Buy
+131.7% avg upside
26 analysts
$25.00
253.37% Upside
 -16.6% ·
ADAG
Adagene
 Sep 14, 2026 BUY Strong Buy
+140.8% avg upside
8 analysts
$7.00
118.84% Upside
 -10.4% ·
IMA
ImageneBio
 Aug 21, 2026 BUY Strong Buy
+290.6% avg upside
13 analysts
$28.00
511.41% Upside
 -15.8% ·
VERA
Vera Therapeutics
 Aug 12, 2026 BUY Strong Buy
+110.3% avg upside
19 analysts
$90.00
185.10% Upside
 +8.4% ·
AUPH
Aurinia Pharmaceuticals
 Feb 27, 2026 BUY Strong Buy
-1.7% avg upside
12 analysts
$17.00
6.50% Upside
 +16.0% ·
BCAB
BioAtla
 Aug 11, 2025 HOLD Strong Buy
+7209.1% avg upside
13 analysts
 — -80.7% ·
ADAPY
Adaptimmune Therapeutics
 Jul 29, 2025 HOLD Buy
+6072.2% avg upside
10 analysts
 — -69.5% ·
M
Macy's
 Jun 21, 2024 BUY Buy
+142.4% avg upside
35 analysts
 — -36.4% ·
HK:1952
Everest Medicines Ltd.
 Apr 03, 2023 BUY Buy
+70.6% avg upside
3 analysts
$35.00
16.22% Upside
 +56.5% ·
🔒 8 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Arthur He CFA — Frequently Asked Questions
How accurate are Arthur He CFA's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Arthur's ratings were profitable over a one-year hold, with an average return of -5.0% per rating, or -9.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Arthur ranked on 13Foresight?
Arthur He CFA is currently ranked #2667 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Arthur cover?
Arthur most recently has ratings on PRME, JBIO, NKTR, TSE:MSCL, SLDB, ADAG, IMA, VERA, AUPH, BCAB, ADAPY, M and 1 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.